LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA) |
Catalog No.GC39398 |
LSKL, 트롬보스폰딘(TSP-1) 억제제 TFA는 잠복기 관련 단백질(LAP)-TGFβ 유래 테트라펩타이드이자 경쟁적인 TGF-β1 길항제입니다. LSKL, 트롬보스폰딘(TSP-1) 억제제 TFA는 LAP에 대한 TSP-1의 결합을 억제하고 신장 간질 섬유증 및 간 섬유증을 완화합니다. LSKL, 트롬보스폰딘(TSP-1) 억제제 TFA는 TSP-1 매개 TGF-β1 활성 억제를 통해 지주막하 섬유증을 억제하고 만성 뇌수종 발병을 예방하며 지주막하 출혈(SAH) 후 장기간 신경인지 결함을 개선합니다. LSKL, 트롬보스폰딘(TSP-1) 억제제 TFA는 혈액-뇌 장벽을 쉽게 통과할 수 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier[1][2].
[1]. Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Exp Ther Med. 2016 Oct;12(4):2537-2543. Epub 2016 Aug 31. [2]. Laurent MA, et al. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1. Comput Biol Chem. 2016 Apr;61:155-61. [3]. Kuroki H, et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model. Br J Surg. 2015 Jun;102(7):813-25.
Average Rating: 5
(Based on Reviews and 35 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *